2026-06-09

[2026-06-09] log

[2026-06-09] ingest | injectable skin boosters (full build-out) — from a retracted-paper lead, rebuilt on a clean replacement (user-prompted)

User supplied a Reddit thread (r/DIYmicroneedling) circulating a skin-booster classification, ultimately sourced to Yi KH et al. “Skin boosters: Definitions and varied classifications,” Skin Research and Technology 2024 (DOI 10.1111/srt.13627). That paper is RETRACTED by Wiley (retraction notice DOI 10.1111/srt.70297, Nov 2025) — insufficient peer review, uncited/unlicensed images, promotional bias, and factual inaccuracies (wrong Restylane durations, mischaracterized Sculptra), per the published Letter to the Editor (Martschin 2024, DOI 10.1111/srt.13827). Per citation discipline it was not cited for any claim. The whole build was anchored instead on a clean, independent, more rigorous review:

Rho NK, Kim HS, Kim SY, Lee W. “Injectable Skin Boosters in Aging Skin Rejuvenation: A Current Overview.” Arch Plast Surg 2024;51(6):528–541. DOI 10.1055/a-2366-3436 · PMID 39544509 · PMC11560330 (gold OA). (The two papers are different author groups in different journals — Rho is not a corrected re-issue of Yi.)

Workflow: 4 parallel seeders (verified:false + banner) → 4 parallel verifiers against the OA Rho PDF + traced primaries → reconciliation/propagation pass. All five new pages end verified:true with explicit partial verified-scope notes (many sub-primaries are non-OA, verified to abstract level).

Added

• added: studies/rho-2024-injectable-skin-boosters.md — type: study, the synthesis anchor (verified:true; PDF read end-to-end).
• added: interventions/pharmacological/injectable-skin-boosters.md — umbrella type: intervention (mode: pharmacological). Encodes Rho’s 5-category classification (natural biopolymers / synthetic biodegradable polymers / other ingredients / polycomponent / + emerging exosomes), injection technique, safety, regulatory framing, and a documented retraction note (RETRACTED-footnote convention) for the Yi paper. Cross-links HA, PDRN, biostimulators, exosomes, microneedling, retinoids.
• added: molecules/compounds/pdrn.md — type: compound polydeoxyribonucleotide / polynucleotides (salmon-DNA biostimulator). Mechanism arms: adenosine A2A-receptor agonism (DMPX-reversal anchored; downstream macrophage→fibroblast collagen relay characterized by Byun 2025), nucleotide salvage, physical scaffold. pubchem-cid null (heterogeneous mixture; gap/needs-canonical-id). Defibrotide (DB01254) flagged as distinct, do-not-conflate.
• added: interventions/pharmacological/biostimulatory-fillers.md — type: intervention class page covering PLLA/PDLLA/PCL/PDO/CaHA collagen-stimulation (M1→M2→TGF-β/SMAD neocollagenesis). Hard disambiguation of aesthetic CaHA from vascular/ectopic calcification.
• added: interventions/pharmacological/exosome-skin-therapy.md — type: intervention aesthetic EV therapy; deliberately conservative (FDA 2019 safety alert; MISEV-noncompliant prep heterogeneity; much “exosome” literature is actually conditioned media). clinical-stage: preclinical.
• added: molecules/proteins/adora2a.md — #stub for the PDRN target (Adenosine A2A receptor; IDs verified vs UniProt: P29274 / gene 135 / HGNC 263 / ENSG00000128271).

Verifier corrections (high-error-rate seed, as usual)

• PDRN — critical: seeder had absorbed n=72 from the retracted Pak 2014 paper as if it were the Lee 2020 RCT; Lee 2020 is actually n=27 and was null on its primary endpoints (VAS/GAIS), with only roughness/pore-volume improving. Corrected throughout; Pak 2014 given a RETRACTED footnote; multiple wrong PMIDs/page-ranges fixed (Bitto 2008 JVS pages, thermal-injury PMID + rat→mouse).
• Umbrella: CD73→adenosine upstream step was unsourced → flagged gap/no-mechanism (not asserted by Byun 2025 or Rho); NCTF135HA “n=50” disentangled (Savoia clinical, distinct from Jäger in-vitro); exosome row relabeled as emerging/not-in-Rho’s-primary-scheme.
• Biostimulators: Porcello 2024 collagen claim overstated → corrected (HAR hydrogels significantly > Radiesse, non-significant trend vs Sculptra); the PDO>PLLA comparative claim re-attributed to Kim CM 2019 (non-retracted) after seeder mis-blamed the retracted Zhou 2023 (PMID 37103107, retracted; confirmed, not cited for any live claim); Nowag 2024 page-range fixed.
• Exosomes: Jafarzadeh 2025 review is 79% conditioned-media, not EVs — scope caveat added; Cui 2025 mechanism sign corrected (net TGF-β1/SMAD activation, not suppression); Fu 2026 central mechanism (ADAM10 suppression) added; clinical-trials-active 2→1 (NCT07281690 is COMPLETED, only NCT06221787 recruiting); FDA-2019-alert URL permanently 404 → gap/needs-fulltext, existence confirmed via secondary citation.

Propagation

• updated: frameworks/intervention-classes.md — reconciled a parallel-seeder edit race: two seeders had created near-duplicate adenosine classes (adenosine-A2A-receptor-agonism vs adenosine-receptor-agonism/a2ar-agonism). Merged into the single canonical adenosine-A2A-receptor-agonism (deprecated-alias note + defensive Dataview OR); added new classes dermal-biostimulation and paracrine-cargo-delivery (for EVs). Page frontmatter mechanisms: standardized to canonical values (biostimulators → immunomodulation for the M2 step; dropped non-canonical foreign-body-inflammatory-resolution/macrophage-m2-polarization).
• updated: inbound cross-links added from phenotypes/skin-aging.md, tissues/dermis.md, cell-types/dermal-fibroblasts.md, molecules/compounds/hyaluronic-acid.md, interventions/procedural/microneedling.md, organ-systems/integumentary-system.md (cluster was otherwise near-orphaned).
• updated: acronyms.md — added A2AR/ADORA2A, CaHA, EV, MISEV, PCL, PDLLA, PDO, PDRN, PLLA, PN, PRP, SVF.
• index.md — no change needed (folder-level navigational catalog, no per-page list).

Conceptual frames touched (paper-impact enumeration)

• Intervention modality: injectable dermal biostimulation as a distinct modality (vs topical retinoids/niacinamide and vs procedural microneedling/resurfacing) — sits in interventions/pharmacological/ per the dermatologic-resurfacing/chemical-peels precedent.
• Mechanism taxonomy: two genuinely new mechanism classes formalized (dermal-biostimulation, paracrine-cargo-delivery) + an adenosine-purinergic class.

Gaps surfaced / follow-ups

• #gap/needs-human-replication / #gap/needs-replication — most skin-booster efficacy evidence is small, non-blinded, or Korean-practice-based; no sham-controlled histology-endpoint RCT for any agent. Captured as each page’s next-experiment:.
• #gap/no-mechanism — CD73-mediated adenosine liberation from PN is plausible but unestablished.
• #gap/needs-fulltext — FDA 2019 exosome safety alert (canonical fda.gov URL permanently 404).
• Schema-gap (escalation candidate, not yet actioned): clinical-stage: enum has no value for “approved ex-US (Korea/EU), investigational in US” — PDRN currently uses phase-2 as a surrogate with a body disclaimer. Flagged by both seeder and verifier; left for user decision on whether to add approved-ex-us to the enum in schema-history.
• Pre-existing dangling stub [[tgf-beta-smad]] (6 inbound refs from col1a1/sparc/purohit) noted in passing — not introduced here (biostimulators page points at the existing [[tgf-beta]]); candidate for a future pathway stub.

[2026-06-09] ingest | dietary sodium restriction (seed) — user-prompted; cardiovascular-aging lever

Ad-hoc seed: interventions/dietary/sodium-restriction.md plus 4 study pages and 1 mechanism-class addition. Motivated by: wiki has [[arterial-stiffening]], [[atherosclerosis]], [[cardiovascular-aging]] but no sodium page. Two primary sources pre-verified by user (Kong 2025, Granal 2025); remaining sources resolved via Crossref/PubMed by seeder.

Added

• added: interventions/dietary/sodium-restriction.md — type: intervention, mode: dietary, human-evidence-level: strong, clinical-stage: implemented. Full J-curve controversy section; companion-cation (K + Mg) section with real Argeros 2025 Mg-BP numbers; salt-substitute hyperkalemia caveat; SSaSS hard-endpoint data; TOHP Na/K-ratio framing; DASH-Sodium dose-response.
• added: studies/kong-2025-sodium-umbrella-review.md — umbrella review, 21 meta-analyses/91 outcomes. Headline source; directly refutes PURE J-curve.
• added: studies/granal-2025-potassium-bp-meta.md — dose-response meta-analysis, 10 RCTs, potassium and BP. New result.
• added: studies/odonnell-2014-pure-sodium.md — PURE J-curve (contested observational; preserved as counterposition).
• added: studies/neal-2021-ssass-salt-substitute.md — SSaSS cluster-RCT, n=20,995; hard-endpoint anchor.
• added: studies/cook-2009-tohp-sodium-potassium.md — TOHP 10–15-year follow-up; Na/K ratio framing.

Updated

• updated: frameworks/intervention-classes.md — new class blood-pressure-modulation (canonical values dietary-sodium-restriction, potassium-repletion, blood-pressure-modulation) added per R16 discipline before shipping the intervention page.

Source resolution

• Intersalt (BMJ 1988 doi:10.1136/bmj.297.6644.319): confirmed via Crossref; cited inline without full study page.
• Aburto 2013 (BMJ doi:10.1136/bmj.f1378): confirmed; cited inline.
• DASH-Sodium/Sacks 2001 (NEJM doi:10.1056/NEJM200101043440101, PMID 11136953): confirmed; cited inline.
• Argeros 2025 (Hypertension doi:10.1161/HYPERTENSIONAHA.125.25129, PMID 41000008): confirmed; integrated into Mg section.
• Wilck 2017 (Nature doi:10.1038/nature24628): training knowledge + citation format; NF-κB/TH17 mechanistic claim.
• UNRESOLVABLE: Kempner/Duke rice-diet 1940s historical paper — pre-MEDLINE; no PMID found; historical context only, no claim cited.
• ClinicalTrials.gov query returned ~32 active trials for “sodium reduction blood pressure” (v2 API count).

R25 recency search (mandatory — dietary intervention)

• Window: 2021–2026-06-09.
• High-priority hits: Kong 2025 (integrated), Granal 2025 (integrated), Argeros 2025 (integrated), Yang 2025 Critical Rev Food Sci (umbrella review — consistent with Kong; noted but not separately footnoted), Greenwood 2024 Ann Intern Med (salt-substitute meta-analysis; cited as [
• Key contradiction framing: Kong 2025 vs PURE J-curve. Discordance framed explicitly in J-curve controversy section. literature-checked-through: 2026-06-09 set.

Gaps surfaced

• #gap/contradictory-evidence — PURE J-curve vs Kong 2025 linear dose-response; framed explicitly on sodium-restriction intervention page.
• #gap/dose-response-unclear — optimal sodium floor (below 1.5 g/day) not well characterized.
• #gap/no-mechanism — independent Mg effect on BP in normomagnesemic normotensives is unclear.
• #gap/needs-human-replication — Americas regional non-significance in Kong 2025; SSaSS generalizability to non-Chinese populations.
• Implicit stubs created: [[dash-diet]] (no page), [[cardiovascular-aging]] (check), [[wilck2017]] study footnote (no separate study page; inline DOI format used).

[2026-06-09] verify | sodium-restriction cluster (6 pages)

Verified the 2026-06-09 sodium-restriction seed against primary PDFs (PMC/NEJM OA copies). Cook 2009 TOHP unverifiable (closed-access download failed).

Pages verified: true

• studies/kong-2025-sodium-umbrella-review.md — all effect sizes confirmed (RRs, ORs, BP MDs, RAAS values, dose-response Table 2, subgroups Table 1). No corrections needed to quantitative claims.
• studies/neal-2021-ssass-salt-substitute.md — 3 corrections: (1) salt composition 75%/25% NaCl/KCl → ~70%/~30% per GB 2019-2005; (2) BP reduction “approximately −3 mmHg” → measured −3.34 mmHg (95% CI −4.51 to −2.18); (3) CKD exclusion criterion clarified as “known serious kidney disease” by self-report (no biochemical pre-screening performed). Rate ratios and CIs confirmed.
• studies/granal-2025-potassium-bp-meta.md — all dose-response values confirmed; n=684 total added to body.
• studies/odonnell-2014-pure-sodium.md — 1 correction: country count 18→17 (paper states 17 countries); OR values and CI ranges confirmed from Table 2 primary analysis.
• interventions/dietary/sodium-restriction.md — corrections propagated from above; additionally: PURE country count 18→17 fixed throughout (body + footnote); SSaSS 75/25→70/30 fixed throughout; SSaSS BP updated to −3.34 mmHg; Argeros 2025 hypertensive subgroup disambiguated (all-HTN subtotal −2.96 mmHg per Figure 4 vs HTN-on-medication −7.68 mmHg — wiki had conflated these).

Pages not flipped (verified: false retained)

• studies/cook-2009-tohp-sodium-potassium.md — closed-access, download failed; gap/no-fulltext-access added to banner. Core claims (p-values for Na/K ratio, Na alone, K alone) uncorroborated by primary PDF but internally consistent with SSaSS discussion and subsequent meta-analyses that cite TOHP.

Kempner claim resolution

Specific numbers (95.6% 5-year survival, 17,000 patients) were correctly absent from all pages — the seeder excluded them. No paper found on PubMed matching a digitized-records analysis with those specific statistics. No action needed.

Wilck 2017 DOI

Confirmed via Crossref: doi:10.1038/nature24628 → “Salt-responsive gut commensal modulates TH17 axis and disease” — correct paper, correct claim direction.

R25 supersession check

• Zhang 2025 (Nutr Rev, 43 RCTs, 2025) — consistent with Kong 2025, confirms graded sodium-BP association. No supersession.
• SSaSS secondary analyses (cardiac outcomes, fractures, 2024) — consistent with/extending original findings. No supersession.
• No contradicting large RCT or meta-analysis found post-Kong 2025.
• literature-checked-through: 2026-06-09 confirmed on all pages.

Downstream propagation needed

• studies/neal-2021-ssass-salt-substitute.md salt composition correction (70/30 not 75/25) should be checked in any page that quotes “75% NaCl / 25% KCl” — notably interventions/dietary/sodium-restriction.md (already corrected this pass) and any future pages that cite SSaSS.

[2026-06-09] schema | R52 — clinical-stage: approved-ex-us

New clinical-stage: enum value approved-ex-us (full rationale in schema-history § R52). Surfaced by the injectable-skin-boosters build (both seeder + verifier escalated that the enum had no value for “approved by a stringent non-US regulator but not FDA,” forcing a phase-2 surrogate on pdrn). User confirmed and broadened the motivation: ex-US (EMA/MFDS/PMDA/MHRA) approval is not a weaker signal than FDA approval and is sometimes stronger/earlier — the US OTC sunscreen-monograph backlog and FDA’s drug-vs-cosmetic split mean “not FDA-approved” often reflects US regulatory lag, not weak evidence.

• added: enum value in CLAUDE.md type: compound block + a dedicated “Ex-US regulatory-approval convention (R52)” paragraph in the druggability-conventions section; R52 entry in schema-history.md.
• applied: pdrn phase-2 → approved-ex-us (body regulatory note rewritten). Semantics: approved in BOTH US + ex-US → still fda-approved (body notes the rest); approved-ex-us is the US-gap case.

[2026-06-09] ingest | EU/global UV-filter cluster (seed + verify) — applying R52 (user-prompted)

Direct follow-on to R52: seeded the EU/global-approved-but-not-FDA sunscreen UV filters, which existed only as in-prose discussion inside the umbrella uv-protection (verified) + two prior dedicated pages (triasorb, mexoryl-400). 6 seeders → 3 paired verifiers → propagation. All 6 new pages verified:true (partial scope — canonical IDs confirmed via live PubChem/ChEMBL/OpenFDA APIs; many primaries closed-access, claims hedged).

Added (all type: compound, administration-route: topical)

• added: molecules/compounds/bemotrizinol.md (Tinosorb S / BEMT; broad-spectrum triazine, avobenzone photostabilizer; the R52 flagship; approved-ex-us; CID 135487856; Wang 2026 “FDA approval pending” integrated).
• added: molecules/compounds/bisoctrizole.md (Tinosorb M / MBBT; hybrid absorber+scatterer; approved-ex-us; CID 3571576).
• added: molecules/compounds/drometrizole-trisiloxane.md (Mexoryl XL / DRT; organosilicone broad-spectrum; approved-ex-us; CID 9848888).
• added: molecules/compounds/iscotrizinol.md (Uvasorb HEB / DBT; UVB; thinnest evidence — human-evidence-level: preclinical-only; approved-ex-us; CID 9810816).
• added: molecules/compounds/tinosorb-a2b.md (tris-biphenyl triazine / TBPT; newest, net-new to wiki; approved-ex-us; CID 11628027 — explicitly disambiguated from TriAsorB CID 59516799).
• added: molecules/compounds/ecamsule.md (Mexoryl SX / TDSA; special case → fda-approved via product-specific NDA021502 Anthelios SX, NOT OTC-monograph/GRASE; EU-approved too; CID 146382).

Verifier corrections (high-error-rate seed)

• bemotrizinol: fabricated D’Ruiz 2023 author list corrected against Crossref; Puglia 2014 pages fixed; ChEMBL added.
• bisoctrizole: Gonzalez 2011 issue/pages fixed; InChIKey added; Naumov 2020 DOI unconfirmable → flagged.
• drometrizole-trisiloxane: six citation errors fixed (Stege/Moyal-DOI/Antoniou-DOI/Hughes/Pastor-Nieto/Carrera — one DOI resolved to an unrelated 1989 neurosurgery paper → #gap/unverifiable-doi).
• ecamsule: seeder’s NDA “22-015” does not exist → corrected to NDA021502 (+021501/021471/022009) via OpenFDA; DeLeo 2009 is in Cutis not JAAD; Moyal DOI fixed.
• iscotrizinol + tinosorb-a2b: translation-gap enum corrected (human-evidence-strong → preclinical-only); A2B’s seeder-guessed SCCS/1533/14 was wrong (= Acid Orange 7) → removed; Tinosorb A2B ≠ TriAsorB confirmed (CID/CAS/scaffold).
• Recurring #gap: EU Annex VI entry numbers + SCCS opinion numbers could not be confirmed against primary EU docs (EUR-Lex/CosIng endpoints unreachable) → #gap/needs-canonical-id retained on all.

Propagation

• updated: frameworks/intervention-classes.md — UV-filter class: accepted the shorter UV-filter-absorption as an equivalent value (the compound pages use it ± a filter-specific descriptor) and added it to the class Dataview OR, so all 8 filter pages resolve (the canonical class string is UV-filter-absorption-scattering; seeders had split between the two forms).
• updated: molecules/compounds/triasorb.md + mexoryl-400.md — clinical-stage: fda-approved → approved-ex-us (R52 correction; both bodies already said “Not FDA-GRASE”; both are verified:false so no scope change).
• updated: interventions/lifestyle/uv-protection.md — wired the 6 new filters as wikilinks into existing prose + a dedicated-pages note; corrected a misleading line (ecamsule is FDA-approved via NDA021502, not “not FDA-approved”); kept verified:true with a dated verified-scope addendum. Matta-2019 Cmax numbers deliberately left untouched — see gap below.
• updated: interventions/pharmacological/retinoids.md — de-staled “(R42 forward-ref; page pending)” notes for pages that now exist (uv-protection, niacinamide, ascorbic-acid, skin-aging); left ap-1-pathway flagged (still genuinely missing).
• updated: acronyms.md — BEMT, MBBT, DBT, DRT, TBPT, TDSA.

Gaps surfaced / follow-ups

• #gap/contradictory-evidence (flagged, NOT auto-fixed): the ecamsule verifier (reading the Matta 2019 abstract) reports avobenzone Cmax 1.8–4.3 / octocrylene 2.9–7.8 ng/mL, whereas the verified uv-protection page states 4.0–8.7 / 4.5–7.8 (likely a Matta 2019 vs 2020 / formulation-range difference). Not reconciled by overwriting a verified quantitative claim on a single abstract read (verifier-introduced-error risk) — needs a dedicated pass reading both JAMA papers (Matta 2019 doi:10.1001/jama.2019.5586; Matta 2020 doi:10.1001/jama.2019.20747).
• #gap/needs-canonical-id — EU Annex VI entry numbers + SCCS opinion numbers across all 6 filters (primary EU endpoints unreachable this pass).
• #gap — not part of this EU-not-FDA cluster (deferred): zinc oxide + titanium dioxide (the two FDA GRASE Cat-I mineral filters) and the US-GRASE organics (avobenzone/oxybenzone/octinoxate/octocrylene/homosalate/octisalate) still have no atomic pages, only umbrella discussion.

[2026-06-09] ingest | thymic health (Bernatz/Aerts 2026 Nature companion papers) — user-prompted

User supplied two Nature companion papers (same lead group: Bernatz, Prudente, Pai; senior Aerts/Birkbak/Swanton/Jamal-Hanjani), both 2026-03-18: a deep-learning thymic health score from routine chest CT, validated for (a) mortality/cancer incidence in asymptomatic adults and (b) immunotherapy outcomes in cancer patients. Both closed-access; not in the local store — drafted from abstracts + reputable secondary coverage (ASCO Post, press releases). All new pages verified: false + ⚠️ banner + #gap/no-fulltext-access; effect sizes flagged approximate.

Added

• added: studies/bernatz-2026-thymic-health-adults.md (doi:10.1038/s41586-026-10242-y) — observational imaging, n≈27,612 (NLST 25,031 + Framingham 2,581). High vs low thymic health: ~50% lower all-cause / ~63% lower CV mortality / ~36% lower lung-cancer incidence; CV-mortality association replicated independently in Framingham; inverse correlation with IL-6/inflammation.
• added: studies/bernatz-2026-thymic-health-immunotherapy.md (doi:10.1038/s41586-026-10243-x) — observational, n≈3,476 pan-cancer immune-checkpoint-inhibitor cohort + TRACERx molecular validation. Higher thymic health → better NSCLC progression/mortality on ICB, independent of PD-L1 and TMB; correlates with TCR diversity + TRECs. Exact HRs not retrievable from secondary sources.
• added: biomarkers/thymic-health-score.md — type: biomarker, modality: imaging, unit: composite-score, mendelian-randomization: not-applicable (structural imaging readout, AGE-Reader precedent), human-evidence-level: limited (single group, 2026, unreplicated externally), literature-checked-through: 2026-06-09. Fills the wiki’s gap of having no immune-aging/thymic imaging biomarker (complements NLR/IL-6 inflammatory indices on a different — thymic-output — axis). model-architecture: composite-other / training-target: morbidity flagged as best-fit placeholders (true training labels unverifiable from available text).

Propagation

• updated: tissues/thymus.md — un-stubbed (removed #stub); expanded into a full tissue page: involution biology (FOXN1/sex-steroid driver, ~16%→<1% output) cross-linked to disabled-adaptive-immunity, plus a new “Thymic health is prognostic” section with both 2026 papers + footnotes.
• updated: phenotypes/immunosenescence.md (verified:true) — added a paragraph to § Thymic involution noting it is now quantifiable at scale and prognostic; new [^bernatzThymicHealth2026] footnote. New claim carries its own #gap/no-fulltext-access + #gap/needs-replication (consistent with the page’s existing not_oa-claim handling).
• updated: hallmarks/disabled-adaptive-immunity.md (verified:true) — two additions: (1) § Thymic involution — population-scale prognostic readout paragraph; (2) § Decision framework: target immunogenicity — new paragraph establishing host adaptive-immune competence (thymic health) as the host-side axis that gates the entire Side-B (augmentation) column, anchored on the immunotherapy paper’s PD-L1/TMB-independence. Two new footnotes. literature-checked-through left at 2026-05-07 (no full re-sweep performed).
• updated: organ-systems/immune-system.md (navigational) — added [[thymus]] to key-tissues; thymus moved from “missing/planned stub” to written-out; thymic-health-score note added.

Conceptual frames touched (paper-impact enumeration)

• Biomarker modality: first opportunistic-imaging immune-aging biomarker (CT-derived); distinct axis from methylation/proteomic clocks (organ-specific) and from inflammatory indices (upstream of them).
• Hypothesis: population-scale outcome evidence that thymic involution is not benign — bears on immunosenescence-as-hallmark case (disabled-adaptive-immunity § case for elevation).
• Intervention/clinical: host immune fitness as a checkpoint-inhibitor response predictor, orthogonal to tumor-intrinsic PD-L1/TMB.

Gaps surfaced / follow-ups

• #gap/no-fulltext-access — both papers closed-access, not in local store; all extracted numerics are abstract/secondary-source level. Verification deferred until full text obtainable (try PMC once OA, or direct request).
• #gap/needs-replication — single group, single deep-learning method, 2026; no external-team replication yet.
• #gap/no-mechanism — associations observational; thymic health may partly mark systemic health rather than drive outcomes.
• Candidate future pages: [[t-cells]] / [[naive-t-cells]] / [[thymic-epithelial-cells]] cell-type stubs (referenced but absent); a methods/ radiomics/deep-learning-imaging-biomarker page once a 3rd citing page exists (currently 2 — below the ≥3 triage threshold).